Compare MaxLinear Inc. Common Stock (MXL) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MaxLinear Inc. Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? MaxLinear Inc. Common Stock trades at $77.05 (market cap $8.04B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: MaxLinear Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (490,798 versus 2,554,408). Which is the better fit depends on your goals — on Pluang, investors hold MaxLinear Inc. Common Stock for 3 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| MXL | ORKA | |
|---|---|---|
Market Cap | $8.04B | $5.18B |
Volume | 2,554,408 | 490,798 |
Sector | Technology | Health |
52-Week High | $128.03 | $113.08 |
52-Week Low | $13.05 | $26.19 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $8.12B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MaxLinear (MXL) trades at $88.64, down 0.39% on the day, with strong technical momentum indicated by bullish moving averages and key support at $87. The company shows impressive revenue growth with Q2 2026 EPS beating expectations at $0.35 versus $0.33, though profitability remains challenged with a -18.24% net income margin. Recent AI-focused product launches like Topaz™ PON chips and strong infrastructure demand position MXL for continued growth.
MXL presents a compelling growth story driven by AI infrastructure demand, with analyst consensus at Buy (64.7%) and $91.67 price target offering 3.4% upside. However, negative profitability metrics and cash flow concerns require careful monitoring. The stock's 50.7% September surge (Motley Fool, Oct 2) reflects optimism, but execution risks and valuation premium warrant cautious optimism for long-term investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MaxLinear Inc. Common Stock
MaxLinear develops analog and mixed-signal semiconductors for connectivity, communications, industrial, and data center applications.
Read more on MXL →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
